Catalog No.: PC-49639Not For Human Use, Lab Use Only.
HQL-79 (HQL79) is an orally selective inhibitor of human hematopoietic prostaglandin D synthase (H-PGDS), inhibits human H-PGDS competitively against the substrate PGH2 and non-competitively against GSH with Ki of 5 and 3 uM, respectively.
HQL-79 (HQL79) is an orally selective inhibitor of human hematopoietic prostaglandin D synthase (H-PGDS), inhibits human H-PGDS competitively against the substrate PGH2 and non-competitively against GSH with Ki of 5 and 3 uM, respectively.
HQL-79 binds to H-PGDS with an affinity that is 12-fold higher in the presence of GSH and Mg2+ (Kd, 0.8 uM) than in their absence.
HQL-79 selectively inhibited PGD2 production by H-PGDS-expressing human megakaryocytes and rat mastocytoma cells with an IC50 value of about 100 uM but only marginally affected the production of other prostanoids.
Orally administered HQL-79 (30 mg/kg body weight) inhibited antigen-induced production of PGD2, without affecting the production of PGE2 and PGF2alpha, and ameliorated airway inflammation in wild-type and human H-PGDS-overexpressing mice.
